POLYMORPHISM OF ANGIOTENSIN-CONVERTING
ENZYME (rs4340) AND DIABETIC NEPHROPATHY IN
CAUCASIANS WITH TYPE 2 DIABETES MELLITUS
Šeruga M, Makuc J,, Završnik M, Cilenšek I, Ekart R, Petrovič D M. Šeruga and J. Makuc contributed equally to this study.
*Corresponding Author: Professor Dr. Daniel Petrovič, M.D., Ph.D., Institute of Histology and Embryology, Faculty of
Medicine, University of Ljubljana, Korytkova 2, 1000 Ljubljana, Slovenia. Tel: +386-1-543-7360. Fax: +386-1-543-7361.
E-mail: daniel.petrovic@mf.uni-lj.si
page: 29
|
|
RESULTS
The demographic and clinical data of the case and
control groups are shown in Table 1. There were no significant
differences between the groups with respect to
age, sex, duration of diabetes, diastolic blood pressure, body mass index (BMI), smoking status, duration of DR,
serum hemoglobin (Hb), estimated glomerular filtration
rate (eGFR), TG and total HDL, LDL and cholesterol
levels. However, statistically significant differences were
observed in the duration of hypertension, systolic blood
pressure, Hb A1c, fasting-serum glucose, serum urea, serum
creatinine, and urine albumin/creatinine ratio.
Differences in parameters reflecting renal function
(serum creatinine, cystatin C, eGFR and urine albumin/
creatinine ratio) confirmed chronic kidney disease in the
DN+ group. Cystatin C was a better marker for the assessment
of renal function than eGFR (MDRD equation
mL/ min.). Cystatin C was significantly higher in the DN+
group (p <0.001) than in the control group. Univariate
analysis demonstrated a statistically significant difference
in genotype distribution in rs4340 genotypes (Table 2).
We used logistic regression analysis to evaluate
whether this single nucleotide polymorphism (SNP) was
independently associated with DN after adjusting for duration
of hypertension, systolic blood pressure, cardiovascular
disease, DR, diabetic foot, Hb A1c, serum fasting
glucose, serum urea, serum creatinine, serum cystatin C,
urine albumin/creatinine ratio (g/mol), and found no statistically
significant association of rs4340 with DN (Table 3).
|
|
|
|
 |
Number 27
VOL. 27 (2), 2024 |
Number 27
VOL. 27 (1), 2024 |
Number 26
Number 26 VOL. 26(2), 2023 All in one |
Number 26
VOL. 26(2), 2023 |
Number 26
VOL. 26, 2023 Supplement |
Number 26
VOL. 26(1), 2023 |
Number 25
VOL. 25(2), 2022 |
Number 25
VOL. 25 (1), 2022 |
Number 24
VOL. 24(2), 2021 |
Number 24
VOL. 24(1), 2021 |
Number 23
VOL. 23(2), 2020 |
Number 22
VOL. 22(2), 2019 |
Number 22
VOL. 22(1), 2019 |
Number 22
VOL. 22, 2019 Supplement |
Number 21
VOL. 21(2), 2018 |
Number 21
VOL. 21 (1), 2018 |
Number 21
VOL. 21, 2018 Supplement |
Number 20
VOL. 20 (2), 2017 |
Number 20
VOL. 20 (1), 2017 |
Number 19
VOL. 19 (2), 2016 |
Number 19
VOL. 19 (1), 2016 |
Number 18
VOL. 18 (2), 2015 |
Number 18
VOL. 18 (1), 2015 |
Number 17
VOL. 17 (2), 2014 |
Number 17
VOL. 17 (1), 2014 |
Number 16
VOL. 16 (2), 2013 |
Number 16
VOL. 16 (1), 2013 |
Number 15
VOL. 15 (2), 2012 |
Number 15
VOL. 15, 2012 Supplement |
Number 15
Vol. 15 (1), 2012 |
Number 14
14 - Vol. 14 (2), 2011 |
Number 14
The 9th Balkan Congress of Medical Genetics |
Number 14
14 - Vol. 14 (1), 2011 |
Number 13
Vol. 13 (2), 2010 |
Number 13
Vol.13 (1), 2010 |
Number 12
Vol.12 (2), 2009 |
Number 12
Vol.12 (1), 2009 |
Number 11
Vol.11 (2),2008 |
Number 11
Vol.11 (1),2008 |
Number 10
Vol.10 (2), 2007 |
Number 10
10 (1),2007 |
Number 9
1&2, 2006 |
Number 9
3&4, 2006 |
Number 8
1&2, 2005 |
Number 8
3&4, 2004 |
Number 7
1&2, 2004 |
Number 6
3&4, 2003 |
Number 6
1&2, 2003 |
Number 5
3&4, 2002 |
Number 5
1&2, 2002 |
Number 4
Vol.3 (4), 2000 |
Number 4
Vol.2 (4), 1999 |
Number 4
Vol.1 (4), 1998 |
Number 4
3&4, 2001 |
Number 4
1&2, 2001 |
Number 3
Vol.3 (3), 2000 |
Number 3
Vol.2 (3), 1999 |
Number 3
Vol.1 (3), 1998 |
Number 2
Vol.3(2), 2000 |
Number 2
Vol.1 (2), 1998 |
Number 2
Vol.2 (2), 1999 |
Number 1
Vol.3 (1), 2000 |
Number 1
Vol.2 (1), 1999 |
Number 1
Vol.1 (1), 1998 |
|
|
